BioCardia BCDA 深 滬
等待開盤 09-17 09:30:00 美东时间
1.25
+0.020
+1.63%
華盛通- 最 高1.40
- 今 開1.24
- 成交量 152.93万股
- 最 低 1.13
- 昨 收 1.23
- 總市值 1892.35万
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 10.10%
- 52周最低 0.75
- 委 比 88.86%
- 總股本 1513.88万
- 歷史最高 129.00
- 量 比 5.37
- 振 幅 21.95%
- 歷史最低 0.75
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioCardia Highlights Therapeutic Pipeline at Investor Conference
BioCardia ( ($BCDA) ) has issued an announcement. On September 10, 2026, BioCar...
09-10 21:23
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
BioCardia reported Q2 2026 financial results, including a net loss of $1.6M, decreased R&D expenses, and $4.1M cash runway. Key regulatory progress includes Japan PMDA support for CardiAMP submission and FDA feedback on potential U.S. approval. Business highlights include positive clinical outcomes for CardiAMP in heart failure and refractory angina, and progress on Helix and Heart3D platforms. Upcoming milestones include Q4 Japan submission and ...
08-12 20:05
BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
BioCardia, Inc. will host a conference call on August 12, 2026 at 4:30 PM EDT to discuss its second-quarter 2026 financial results and provide a corporate update. Registration for the call is available at [link]. U.S. callers can dial 1-833-316-0559, while international callers can dial 1-412-317-5730. A live webcast will be available at [link], and a replay will be accessible starting one hour after the call through November 12, 2026 at [link]. ...
08-05 19:16
美股夜盘 | Pineapple Financial Inc.涨34.47%，Advanced Biomed涨18.88%
Eva Live Inc涨-12.29%；Globavend Holdings涨-10.81%；BioCardia涨-5.70%
07-21 08:05
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
BioCardia Inc., a global leader in cellular and cell-derived therapeutics, announced its strategic priorities and business developments. The company is focusing on seeking regulatory approval for its CardiAMP® Cell Therapy in Japan for ischemic heart failure, targeting 20,000 patients initially. Japan's status as a trusted Reference Country and MDSAP member could streamline approvals in other regions. BioCardia is also advancing the CardiAMP HF I...
06-18 12:00
美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
Why Is BioCardia Stock Gaining Friday?
BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 resistance? Get the technical outlook.
06-05 23:06
BioCardia Receives FDA Confirmation For Its Biologics Evaluation And Research On CardiAMP Cell Therapy System To Treat Ischemic Heart Failure Of Reduced Ejection Fraction
BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting
06-05 20:03
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
BioCardia announced FDA meeting minutes supporting potential Premarket Approval (PMA) for its CardiAMP Cell Therapy System to treat ischemic heart failure with reduced ejection fraction (HFrEF). The ongoing CardiAMP Heart Failure II Trial may provide sufficient evidence for PMA, the most rigorous device marketing application. FDA previously acknowledged the therapy's safety, enabling Medicare and Medicaid reimbursement. BioCardia aims to publish ...
06-05 12:00
